183 related articles for article (PubMed ID: 37288738)
1. Is it a chimera? A systematic review of the economic evaluations of CAR-T cell therapy - an update.
Petrou P
Expert Rev Pharmacoecon Outcomes Res; 2023; 23(6):625-650. PubMed ID: 37288738
[TBL] [Abstract][Full Text] [Related]
2. Late relapse after CAR-T cell therapy for adult patients with hematologic malignancies: A definite evidence from systematic review and meta-analysis on individual data.
Zinzi A; Gaio M; Liguori V; Cagnotta C; Paolino D; Paolisso G; Castaldo G; Nicoletti GF; Rossi F; Capuano A; Rafaniello C
Pharmacol Res; 2023 Apr; 190():106742. PubMed ID: 36963592
[TBL] [Abstract][Full Text] [Related]
3. The Economic Burden of CAR T Cell Therapies Ciltacabtagene Autoleucel and Idecabtagene Vicleucel for the Treatment of Adult Patients with Relapsed or Refractory Multiple Myeloma in the US.
Ghanem B; Shi L
BioDrugs; 2022 Nov; 36(6):773-780. PubMed ID: 36167952
[TBL] [Abstract][Full Text] [Related]
4. Next-Generation Chimeric Antigen Receptor T-cells.
Yi D; Gergis M; Hsu J; Yang Y; Bi X; Aljurf M; Gergis U
Hematol Oncol Stem Cell Ther; 2022 Dec; 15(3):117-121. PubMed ID: 36537905
[TBL] [Abstract][Full Text] [Related]
5. Economic Evaluations of Chimeric Antigen Receptor T-Cell Therapies for Hematologic and Solid Malignancies: A Systematic Review.
Thavorn K; Thompson ER; Kumar S; Heiskanen A; Agarwal A; Atkins H; Shorr R; Hawrysh T; Chan KK; Presseau J; Ollendorf DA; Graham ID; Grimshaw JM; Lalu MM; Nochaiwong S; Fergusson DA; Hutton B; Coyle D; Kekre N
Value Health; 2024 Apr; ():. PubMed ID: 38641057
[TBL] [Abstract][Full Text] [Related]
6. Impact of Manufacturing Procedures on CAR T Cell Functionality.
Watanabe N; Mo F; McKenna MK
Front Immunol; 2022; 13():876339. PubMed ID: 35493513
[TBL] [Abstract][Full Text] [Related]
7. Current and Future Perspectives for Chimeric Antigen Receptor T Cells Development in Poland.
Ślebioda TJ; Stanisławowski M; Kaszubowska L; Zaucha JM; Żmijewski MA
Biomedicines; 2022 Nov; 10(11):. PubMed ID: 36428480
[TBL] [Abstract][Full Text] [Related]
8. Cost-Effectiveness of KTE-X19 for Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in the United States.
Shah BD; Smith NJ; Feng C; Jeyakumar S; Castaigne JG; Faghmous I; Masouleh BK; Malone DC; Bishop MR
Adv Ther; 2022 Aug; 39(8):3678-3695. PubMed ID: 35727476
[TBL] [Abstract][Full Text] [Related]
9. Is it a Chimera? A systematic review of the economic evaluations of CAR-T cell therapy.
Petrou P
Expert Rev Pharmacoecon Outcomes Res; 2019 Oct; 19(5):529-536. PubMed ID: 31422712
[No Abstract] [Full Text] [Related]
10. Chimeric Antigen Receptor (CAR) T-Cell Therapy in Hematologic Malignancies: Clinical Implications and Limitations.
Blüm P; Kayser S
Cancers (Basel); 2024 Apr; 16(8):. PubMed ID: 38672680
[TBL] [Abstract][Full Text] [Related]
11. Chimeric antigen receptor T-cell therapy-induced nervous system toxicity: a real-world study based on the FDA Adverse Event Reporting System database.
Ren X; Zhang G; Li G; Wang Y
BMC Cancer; 2024 Jan; 24(1):10. PubMed ID: 38166723
[TBL] [Abstract][Full Text] [Related]
12. Cost-Effectiveness of Chimeric Antigen Receptor T Cell Therapy in Patients with Relapsed or Refractory Large B Cell Lymphoma: No Impact of Site of Care.
Cummings Joyner AK; Snider JT; Wade SW; Wang ST; Buessing MG; Johnson S; Gergis U
Adv Ther; 2022 Aug; 39(8):3560-3577. PubMed ID: 35689726
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of Axicabtagene Ciloleucel and Tisagenlecleucel as Second-line or Later Therapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Choe JH; Abdel-Azim H; Padula WV; Abou-El-Enein M
JAMA Netw Open; 2022 Dec; 5(12):e2245956. PubMed ID: 36520440
[TBL] [Abstract][Full Text] [Related]
14. Challenges raised by the economic evaluation of CAR-T-cell therapies. The review by the French National Authority for Health.
Raimond V; Kaltenbach E; Adam C; Lazzarotto S; Le Galès C; Perrier L; Wittwer J
Bull Cancer; 2021 Dec; 108(12):1162-1169. PubMed ID: 34629167
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness analysis of KTE-X19 CAR T therapy versus real-world standard of care in patients with relapsed/refractory mantle cell lymphoma post BTKi in England.
Petersohn S; Salles G; Wang M; Wu J; Wade SW; Simons CL; Bennison C; Siddiqi R; Peng W; Kloos I; Castaigne G; Hess G
J Med Econ; 2022; 25(1):730-740. PubMed ID: 35611697
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of CAR-T Cell Products Axicabtagene Ciloleucel, Tisagenlecleucel, and Lisocabtagene Maraleucel for the Treatment of Hematologic Malignancies: A Systematic Review and Meta-Analysis.
Meng J; Wu X; Sun Z; Xun R; Liu M; Hu R; Huang J
Front Oncol; 2021; 11():698607. PubMed ID: 34381720
[TBL] [Abstract][Full Text] [Related]
17. Strengthening the CAR-T cell therapeutic application using CRISPR/Cas9 technology.
Sadeqi Nezhad M; Yazdanifar M; Abdollahpour-Alitappeh M; Sattari A; Seifalian A; Bagheri N
Biotechnol Bioeng; 2021 Oct; 118(10):3691-3705. PubMed ID: 34241908
[TBL] [Abstract][Full Text] [Related]
18. How much does the hospital stay for infusion of anti-CD19 CAR-T cells cost to the French National Health Insurance?
Huguet M; Raimond V; Kaltenbach E; Augusto V; Perrier L
Bull Cancer; 2021 Dec; 108(12):1170-1180. PubMed ID: 34561025
[TBL] [Abstract][Full Text] [Related]
19. Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an external historical control study.
Shah BD; Ghobadi A; Oluwole OO; Logan AC; Boissel N; Cassaday RD; Leguay T; Bishop MR; Topp MS; Tzachanis D; O'Dwyer KM; Arellano ML; Lin Y; Baer MR; Schiller GJ; Park JH; Subklewe M; Abedi M; Minnema MC; Wierda WG; DeAngelo DJ; Stiff P; Jeyakumar D; Dong J; Adhikary S; Zhou L; Schuberth PC; Faghmous I; Masouleh BK; Houot R
J Hematol Oncol; 2022 Dec; 15(1):170. PubMed ID: 36494725
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]